Hanmi, “Failure experience of Olmutinib is the most valuable asset”
Hanmi Pharm held a press conference related to the recent olmutinib issue on the 2nd at its head office located in Songpa-gu, Seoul, and answered to questions about Boehringer Ingelheim’s termination on the technology export agreement and the timing to announce the incident.
First, Vice Preside...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
